PT002

PT002 is a small molecule drug candidate being developed by PulmoSIM Therapeutics for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Identified through the company's proprietary PRIMES (Predictive, Re-purposing, Integrated, Multi-omics, Evidence-based Screening) platform, PT002 is a repurposed therapeutic designed to target multiple signaling pathways involved in lung fibrosis and inflammation. The PRIMES platform utilizes artificial intelligence and multi-omics data to identify existing drugs with established safety profiles that can be redirected toward rare respiratory diseases. As of early 2024, PT002 is in the preclinical stage of development, with the developer aiming to provide a more effective treatment option for progressive fibrosing interstitial lung diseases compared to current standard-of-care therapies.